On May, 9 Analysts See $-0.16 EPS for Viking Therapeutics, Inc. (VKTX)

April 17, 2018 - By Eula Gilbert

Viking Therapeutics, Inc. (NASDAQ:VKTX) Corporate Logo

Viking Therapeutics, Inc. (NASDAQ:VKTX)’s quarterly earnings will be revealed On May, 9., Zacks reports. Analysts expect change of 30.43 % or $0.07 from previous year’s $-0.23 earnings per share compared to current’s $-0.16 earnings per share. Wall Street predicts 14.29 % negative EPS growth as of May, 9. On during the last trading session the stock increased $0.02 or 0.40%, reaching $5.04.Viking Therapeutics, Inc. has volume of 705,801 shares. Since April 17, 2017 VKTX has risen 240.16% and is uptrending. VKTX outperformed the S&P500 by 228.61%.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Ratings Coverage

In total 2 analysts cover Viking Therapeutics (NASDAQ:VKTX). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 5 are the (NASDAQ:VKTX)’s analyst reports since November 10, 2017 according to StockzIntelligence Inc. The company rating was initiated by Roth Capital on Tuesday, November 21. On Thursday, March 8 the stock has “Buy” rating by Roth Capital. On Monday, March 26 the stock has “Buy” rating by H.C. Wainwright. On Friday, November 10 the rating was reinitiated by H.C. Wainwright with “Buy”. The company rating was maintained by Roth Capital on Wednesday, November 29.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders.The firm is worth $256.70 million. The Company’s lead clinical program is VK5211, an orally available drug candidate, which is in a phase II clinical trials for acute rehabilitation following non-elective hip fracture surgery.Currently it has negative earnings. The firm also develops VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease, as well as for the orphan indication glycogen storage disease type Ia; and VK0214 for the treatment of orphan indication X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.